Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.

Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ, Kelleher AD, Emery S; INSIGHT ESPRIT and SMART Study Groups.

PLoS One. 2015 Oct 14;10(10):e0139981. doi: 10.1371/journal.pone.0139981. eCollection 2015.

2.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

3.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

4.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

5.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

6.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

7.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

8.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

9.

Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial.

Burman W, Grund B, Neuhaus J, Douglas J Jr, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C; SMART Study Group and INSIGHT.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):142-50. doi: 10.1097/QAI.0b013e318183a9ad.

10.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
11.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
12.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
13.

Alterations in porcine gastric mucin during the development of experimental ulceration.

Mall AS, Merrifield E, Fourie J, McLeod H, Hickman R.

Digestion. 1997;58(2):138-46.

PMID:
9144303
14.

Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.

Swanepoel CR, Moosa MR, Rowland GF, Meyers AM, Botha BP, Smart AJ, Goodman R, Schall R, Keogh HJ, Merrifield EH.

S Afr Med J. 1996 Oct;86(10):1266-9.

PMID:
8955732
15.

Hydrophobic effects on antibacterial and channel-forming properties of cecropin A-melittin hybrids.

Juvvadi P, Vunnam S, Merrifield EL, Boman HG, Merrifield RB.

J Pept Sci. 1996 Jul-Aug;2(4):223-32.

PMID:
9231329
16.

D-enantiomers of 15-residue cecropin A-melittin hybrids.

Merrifield EL, Mitchell SA, Ubach J, Boman HG, Andreu D, Merrifield RB.

Int J Pept Protein Res. 1995 Sep-Oct;46(3-4):214-20.

PMID:
8537174
17.

Design and synthesis of antimicrobial peptides.

Merrifield RB, Merrifield EL, Juvvadi P, Andreu D, Boman HG.

Ciba Found Symp. 1994;186:5-20; discussion 20-6. Review.

PMID:
7768157
18.

The Erythrina protease inhibitor: interactions with tissue plasminogen activator.

Heussen-Schemmer C, Merrifield EH, Dowdle EB.

Thromb Haemost. 1991 Aug 1;66(2):226-31.

PMID:
1771616
19.

Bacteriophage-associated lyase activity against Klebsiella serotype K64 capsular polysaccharide.

Ravenscroft N, Stephen AM, Merrifield EH.

Carbohydr Res. 1987 Sep 15;167:257-67.

PMID:
3690571
20.

The reactive sites of proteinase inhibitors from Erythrina seeds.

Joubert FJ, Merrifield EH, Dowdle EB.

Int J Biochem. 1987;19(7):601-6.

PMID:
3114019

Supplemental Content

Loading ...
Support Center